Researchers at the National Eye Institute are launching a clinical trial to test the safety of a novel patient-specific, stem cell-based therapy to treat geographic atrophy.
The availability of a new anti–vascular endothelial growth factor therapy brings a new treatment option for retinal specialists and their patients with wet AMD this year.
